Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants

被引:356
作者
Hemann, MT
Bric, A
Teruya-Feldstein, J
Herbst, A
Nilsson, JA
Cordon-Cardo, C
Cleveland, JL
Tansey, WP
Lowe, SW
机构
[1] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[3] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA
关键词
D O I
10.1038/nature03845
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim ( a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.
引用
收藏
页码:807 / 811
页数:5
相关论文
共 30 条
  • [1] THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE
    ADAMS, JM
    HARRIS, AW
    PINKERT, CA
    CORCORAN, LM
    ALEXANDER, WS
    CORY, S
    PALMITER, RD
    BRINSTER, RL
    [J]. NATURE, 1985, 318 (6046) : 533 - 538
  • [2] ALBERT T, 1994, ONCOGENE, V9, P759
  • [3] The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line
    Bemark, M
    Neuberger, MS
    [J]. ONCOGENE, 2000, 19 (30) : 3404 - 3410
  • [4] POINT MUTATIONS IN THE C-MYC TRANSACTIVATION DOMAIN ARE COMMON IN BURKITTS-LYMPHOMA AND MOUSE PLASMACYTOMAS
    BHATIA, K
    HUPPI, K
    SPANGLER, G
    SIWARSKI, D
    IYER, R
    MAGRATH, I
    [J]. NATURE GENETICS, 1993, 5 (01) : 56 - 61
  • [5] BHATIA KG, 1992, CANCER RES, V52, P4273
  • [6] The c-myc transactivation domain is a direct modulator of apoptotic versus proliferative signals
    Chang, DW
    Claassen, GF
    Hann, SR
    Cole, MD
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (12) : 4309 - 4319
  • [7] CLARK HM, 1994, CANCER RES, V54, P3383
  • [8] Cole M D, 1986, Basic Life Sci, V38, P399
  • [9] HUMAN C-MYC ONC GENE IS LOCATED ON THE REGION OF CHROMOSOME-8 THAT IS TRANSLOCATED IN BURKITT-LYMPHOMA CELLS
    DALLAFAVERA, R
    BREGNI, M
    ERIKSON, J
    PATTERSON, D
    GALLO, RC
    CROCE, CM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (24): : 7824 - 7827
  • [10] Dang CV, 1999, MOL CELL BIOL, V19, P1